CLRB

Cellectar Biosciences, Inc. (CLRB) - 2025 Annual Report Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2025. Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company developing cancer treatments using its proprietary Phospholipid Ether Drug Conjugate (PDC) platform. The company focuses on three lead radioconjugate programs: iopofosine I 131 (beta-emitter), CLR 125 (Auger-emitter), and CLR 225 (alpha-emitter). As of December 31, 2025, the company had 11 full-time employees.

Key Financial Metrics

Note: The company has no revenue and operates at a loss. Margins are not applicable.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately 56% ($28.8 million) compared to 2024. This was driven by a 56% reduction in R&D expenses (due to the conclusion of patient enrollment in the Waldenstrom's macroglobulinemia study) and a 55% reduction in G&A expenses (due to workforce reductions and de-emphasized pre-commercialization efforts).
• Capital Raises: The company raised approximately $13.0 million in net proceeds from financing activities in 2025, including a July 2025 underwritten public offering and an October 2025 warrant inducement.
• Stock Split: A 1-for-30 reverse stock split was effected on June 24, 2025, to regain compliance with Nasdaq listing requirements.
• Financial Restatement: The company restated financial statements for 2022, 2023, and certain 2024 interim periods due to material weaknesses in internal controls regarding the accounting of preferred equity, warrants, and stock-based compensation.

Guidance, Outlook, and Risks

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. With approximately $13.2 million in cash as of year-end, the company estimates it can fund operations only into the third quarter of 2026 without additional capital.
• Strategic Alternatives: The company is actively exploring strategic alternatives, including mergers, acquisitions, partnerships, or joint ventures, to secure funding for the development of iopofosine I 131.
• Regulatory Milestones:
  • FDA: Granted Breakthrough Therapy Designation for iopofosine I 131 for relapsed/refractory Waldenstrom's macroglobulinemia (r/r WM) in June 2025.
  • EMA: Received advice that a Conditional Marketing Authorization (CMA) filing for iopofosine I 131 in r/r WM could be acceptable.
  • Next Steps: A confirmatory Phase 3 trial is required for full FDA approval; initiation is dependent on funding.
• Risks: Key risks include the inability to raise additional capital, failure to meet Nasdaq listing standards, reliance on third-party manufacturers, and the uncertainty of clinical trial outcomes. The company also faces risks related to the remediation of material weaknesses in internal controls.

Investor Verification Checklist

• Liquidity Runway: Verify the company's ability to secure funding before Q3 2026 to avoid operational wind-down or bankruptcy.
• Internal Controls: Review the progress of remediation efforts for the material weaknesses in financial reporting that led to the restatement of prior years.
• Strategic Transaction: Monitor announcements regarding the search for a strategic partner or merger to fund the confirmatory Phase 3 trial for iopofosine.
• Regulatory Path: Confirm the timeline and funding requirements for the FDA-mandated confirmatory study for iopofosine I 131.
• Warrant Liability: Assess the impact of outstanding warrant liabilities and potential dilution from future equity raises.